175 related articles for article (PubMed ID: 19567817)
1. Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
Loeffler-Ragg J; Mueller D; Gamerith G; Auer T; Skvortsov S; Sarg B; Skvortsova I; Schmitz KJ; Martin HJ; Krugmann J; Alakus H; Maser E; Menzel J; Hilbe W; Lindner H; Schmid KW; Zwierzina H
Mol Cancer Ther; 2009 Jul; 8(7):1995-2006. PubMed ID: 19567817
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Ebert B; Kisiela M; Wsól V; Maser E
Chem Biol Interact; 2011 May; 191(1-3):239-49. PubMed ID: 21215737
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells.
Qi W; White MC; Choi W; Guo C; Dinney C; McConkey DJ; Siefker-Radtke A
PLoS One; 2013; 8(7):e69509. PubMed ID: 23874968
[TBL] [Abstract][Full Text] [Related]
4. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Ma J; Yan R; Zu X; Cheng JM; Rao K; Liao DF; Cao D
J Biol Chem; 2008 Feb; 283(6):3418-3423. PubMed ID: 18056116
[TBL] [Abstract][Full Text] [Related]
5. Identification of proteasome subunit beta type 6 (PSMB6) associated with deltamethrin resistance in mosquitoes by proteomic and bioassay analyses.
Sun L; Ye Y; Sun H; Yu J; Zhang L; Sun Y; Zhang D; Ma L; Shen B; Zhu C
PLoS One; 2013; 8(6):e65859. PubMed ID: 23762443
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
[TBL] [Abstract][Full Text] [Related]
7. The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells.
Nakamura T; Tanaka K; Matsunobu T; Okada T; Nakatani F; Sakimura R; Hanada M; Iwamoto Y
Int J Oncol; 2007 Oct; 31(4):803-11. PubMed ID: 17786311
[TBL] [Abstract][Full Text] [Related]
8. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Yan R; Zu X; Ma J; Liu Z; Adeyanju M; Cao D
Int J Cancer; 2007 Nov; 121(10):2301-6. PubMed ID: 17597105
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma.
Bavi P; Uddin S; Ahmed M; Jehan Z; Bu R; Abubaker J; Sultana M; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Prabhakaran S; Hussain AR; Al-Kuraya KS
Am J Pathol; 2011 May; 178(5):2109-20. PubMed ID: 21514426
[TBL] [Abstract][Full Text] [Related]
10. 2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma.
Weinkauf M; Zimmermann Y; Hartmann E; Rosenwald A; Rieken M; Pastore A; Hutter G; Hiddemann W; Dreyling M
Electrophoresis; 2009 Mar; 30(6):974-86. PubMed ID: 19309015
[TBL] [Abstract][Full Text] [Related]
11. Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib.
Voutsadakis IA; Patrikidou A; Tsapakidis K; Karagiannaki A; Hatzidaki E; Stathakis NE; Papandreou CN
Int J Colorectal Dis; 2010 Jul; 25(7):795-804. PubMed ID: 20397022
[TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
13. Hsp72 controls bortezomib-induced HepG2 cell death via interaction with pro-apoptotic factors.
Calvaruso G; Giuliano M; Portanova P; Pellerito O; Vento R; Tesoriere G
Oncol Rep; 2007 Aug; 18(2):447-50. PubMed ID: 17611669
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
Vaziri SA; Grabowski DR; Hill J; Rybicki LR; Burk R; Bukowski RM; Ganapathi MK; Ganapathi R
Anticancer Res; 2009 Aug; 29(8):2961-9. PubMed ID: 19661301
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of bortezomib-induced apoptosis by TGF-beta in cultured human Tenon's fibroblasts: contribution of the PI3K/Akt signaling pathway.
Chung EJ; Moon SW; Jung SA; Cho YJ; Kim SW; Lee JH
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6232-7. PubMed ID: 20702821
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells.
Min H; Xu M; Chen ZR; Zhou JD; Huang M; Zheng K; Zou XP
Cancer Chemother Pharmacol; 2014 Jul; 74(1):167-76. PubMed ID: 24842158
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide confers cisplatin resistance in human lung cancer cells through upregulation of aldo-keto reductase 1B10 and proteasome.
Matsunaga T; Yamaji Y; Tomokuni T; Morita H; Morikawa Y; Suzuki A; Yonezawa A; Endo S; Ikari A; Iguchi K; El-Kabbani O; Tajima K; Hara A
Free Radic Res; 2014 Nov; 48(11):1371-85. PubMed ID: 25156503
[TBL] [Abstract][Full Text] [Related]
19. Proteome analysis of rat hepatomas: carcinogen-dependent tumor-associated protein variants.
Zeindl-Eberhart E; Klugbauer S; Dimitrijevic N; Jungblut PR; Lamer S; Rabes HM
Electrophoresis; 2001 Aug; 22(14):3009-18. PubMed ID: 11565795
[TBL] [Abstract][Full Text] [Related]
20. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]